Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07364474 · ClinicalTrials.gov registry record · NA
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
A NA study of Uveal Melanoma, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07364474: Recruiting NA study of Uveal Melanoma, sponsored by Massachusetts General Hospital.
NCT07364474 is a NA study of Uveal Melanoma that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 10 participants, below the 145-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07364474, a NA study of Uveal Melanoma, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) for patients with Uveal Melanoma that has metastasized to the liver.
Primary Outcome
Change in the percentage of CXCL13⁺ CD8⁺ T cells in tumor biopsies between Day 0 (pre-treatment) and Day 28-42 (approximately 3-4 weeks post-treatment), as measured by single-cell RNA sequencing.
Conditions Studied
Interventions
- DRUG Melphalan through Percutaneous Hepatic Perfusion
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-01-27 |
| Est. Completion | 2028-09 |
| Phase | NA |
What NCT07364474 shows while recruiting
NCT07364474 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 145-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Melphalan through Percutaneous Hepatic Perfusion is the first listed.
NCT07364474 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07364474 about?
NCT07364474 is a clinical study titled "Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver". This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) for patients with Uveal Melanoma that has metastasized to the liver.
What is the current status of trial NCT07364474?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2026-01-27. Estimated completion is 2028-09.
What conditions does trial NCT07364474 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT07364474?
The interventions under investigation include: Melphalan through Percutaneous Hepatic Perfusion (DRUG).
Who is sponsoring clinical trial NCT07364474?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07364474 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07364474's enrollment target sits among peer trials
10 27th of 29 higher than 2 of 29 other Uveal Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psychoeducation for Uveal Melanoma
ACTIVE NOT RECRUITING · NA
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI